HR 2672 · 112th Congress 2011–2013, ended

Preserving Access to Orphan Drugs Act of 2011

Latest action · Aug 1, 2011 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedJul 27, 2011
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Preserving Access to Orphan Drugs Act of 2011 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million.

Makes this Act effective as if included in PPACA.

Cosponsors 36

Members who signed on, in the order they did. Signatures ran from Jul 27, 2011 to Dec 13, 2012; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
D-PAJason AltmireOriginalJul 27, 2011
R-ILAdam KinzingerOct 5, 2011
R-PAPatrick MeehanOct 6, 2011
R-MNErik PaulsenOct 13, 2011
D-MABarney FrankOct 24, 2011
D-PAAllyson Y. SchwartzOct 25, 2011
R-CADevin NunesOct 25, 2011
R-TXKevin BradyNov 15, 2011
R-PAMike KellyNov 17, 2011
R-TXMichael C. BurgessNov 18, 2011
D-PATim HoldenNov 18, 2011
R-PAGlenn ThompsonNov 29, 2011
R-TXKenny MarchantDec 2, 2011
R-KSLynn JenkinsDec 6, 2011
R-KYBrett GuthrieDec 7, 2011
D-NYCharles B. RangelDec 13, 2011
R-WVDavid B. McKinleyDec 13, 2011
R-IATom LathamMar 19, 2012
R-GAPaul C. BrounMay 16, 2012
R-OHRobert E. LattaMay 16, 2012
R-TXRon PaulMay 16, 2012
D-CABarbara LeeJun 27, 2012
D-ORKurt SchraderJun 29, 2012
D-NCLarry KissellJul 9, 2012
D-INAndré CarsonJul 10, 2012
D-NYEliot L. EngelJul 11, 2012
D-MORuss CarnahanJul 17, 2012
D-WIRon KindJul 25, 2012
D-MIGary C. PetersJul 31, 2012
D-CALoretta SanchezAug 1, 2012
D-NYWilliam L. OwensAug 1, 2012
D-CTJames A. HimesSep 10, 2012
D-NMMartin HeinrichSep 12, 2012
D-NJAlbio SiresSep 13, 2012
D-MARichard E. NealSep 21, 2012
R-PACharles W. DentDec 13, 2012

Committees 2

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Jul 27, 2011
Health Subcommittee
Referred Aug 1, 2011
HouseWays and Means Committee
Referred Jul 27, 2011
Health Subcommittee
Referred Aug 1, 2011

Actions 3

Everything that happened, newest first.

  1. Aug 1, 2011Referred to the Subcommittee on Health.
  2. Jul 27, 2011Introduced in House
  3. Jul 27, 2011Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: The Congress enacts this bill pursuant to Clause 18 of Section 8 of Article I of the United States Constitution.

The sponsor’s statement, as printed in the page H5661.

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 1423Preserving Access to Orphan Drugs Act of 2011Identical billJul 27, 2011

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers.
Short Titles as Introduced
Preserving Access to Orphan Drugs Act of 2011

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Jul 27, 2011Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.